Discovery Corner

As the ASRM Research Institute moves into its next phase, we are proud to announce the formation of the Research Institute Advisory Committee. This advisory committee, established in December 2021, comes on the heels of the incredible work that the ASRM Research Task Force and the Strategic Research Steering Committee started back in 2017 and completed in 2019, with the development of the Research Blueprint and formation of the ASRM Research Institute. The new Research Institute Advisory Committee will work with ASRM leadership and staff to guide the robust research agenda that was outlined in the Research Blueprint. “At the Institute’s core, we are committed to promoting and facilitating interdisciplinary research activities in the reproductive sciences that will lead to promising discoveries and next-generation reproductive care and health treatments. This is reflected in the ambitious research agenda that the ASRM Strategic Research Task Force and Strategic Steering Committee established from the beginning” says Dr. Chevis Shannon, Chief Education and Science Officer at ASRM. “We are thrilled to welcome this new team of leaders to the Research Institute. Their guidance and support ...
Ferring Pharmaceuticals values innovation; they know that with the right resources and partnerships we can advance the field of reproductive medicine and fuel additional research. Ferring Pharmaceuticals has supported and continues to support philanthropic investments in the ASRM Research Institute. In 2020, Ferring Pharmaceuticals partnered with the Society for Reproductive Endocrinology and Infertility (SREI) and the ASRM Research Institute to establish the REI Fellow’s Young Investigator Research Award. The purpose of this grant award is to support REI fellow-specific research in reproductive medicine. Who is Ferring: Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical company committed to helping people around the world build families and live better lives. How does Ferring’s vision and commitment to research align with the ASRM Research Institute? For 70 years, Ferring has been developing treatments for mothers and babies and has a portfolio covering treatments from conception to birth. Ferring has a robust clinical pipeline investigating numerous compounds at various stages of development. What does Ferring value most from its partnership ...
The Recurrent Pregnancy Loss Association (RPLA) was founded in 2019 by Megan Hanson and Ben Burnham in the wake of their sixth miscarriage; hoping to transform their frustration and pain into something positive and help prevent other couples from enduring the heartache they experienced. In 2020, RPLA approached ASRM to establish and help fund a research grant focused specifically on recurrent pregnancy loss. The first grant funded was recently awarded to Tsegaselassie Workalemahu PhD, MSc (University of Utah). Dr. Workalemahu’s research program is titled " Inherited Genetic Variants and Unexplained Recurrent Pregnancy Loss ”. A little more about RPLA: What is RPLA’s mission and focus? Recurrent Pregnancy Loss Association (RPLA) is dedicated to eliminating recurrent pregnancy loss through the advancement of research into causes and treatments; to providing support and resources to those affected; and to increasing awareness of the impact of miscarriage and fertility challenges on women and families. Why is supporting grant funding at ASRM important to RPLA? As the premier professional society for reproductive medicine, we believe ASRM’s membership includes professionals ...
Grant Project Title: Characterizing Fertility Concerns among Women in Academic Medicine and Evaluating the Economic Impact of Fertility Preservation for Deferred Reproduction Grant Amount: $50,000 Significance: Although women are more likely than men to pursue a career in academic medicine, they also tend to leave academic medicine, reduce their work hours, or reroute their careers during their childbearing years. In addition, many female physicians delay childbearing, and studies have documented higher rates of infertility, obstetric complications, and childlessness in female physicians relative to the general population. Female physicians report high levels of interest in fertility preservation and assisted reproduction technology (ART) options. Two primary factors that may prevent women in academic medicine from undergoing oocyte vitrification at younger ages (≤ 35 years old) include a lack of awareness regarding the importance of age on the efficiency and success of fertility preservation and the high costs of fertility preservation without adequate insurance coverage. The purpose of this project was to investigate and characterize the unique fertility concerns of women ...